Your browser doesn't support javascript.
loading
DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness.
Carrier, Arnaud; Desjobert, Cécile; Ponger, Loic; Lamant, Laurence; Bustos, Matias; Torres-Ferreira, Jorge; Henrique, Rui; Jeronimo, Carmen; Lanfrancone, Luisa; Delmas, Audrey; Favre, Gilles; Daunay, Antoine; Busato, Florence; Hoon, Dave S B; Tost, Jorg; Etievant, Chantal; Riond, Joëlle; Arimondo, Paola B.
Affiliation
  • Carrier A; Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Epigenetic Targeting of Cancer (ETaC), Toulouse, France.
  • Desjobert C; Cancer Epigenetics Group, Josep Carreras Leukemia Research Institute (IJC), Barcelona, Spain.
  • Ponger L; Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Epigenetic Targeting of Cancer (ETaC), Toulouse, France.
  • Lamant L; CNRS UMR 7196, INSERM U1154, Sorbone university- National museum of natural history (NMNH), Paris, France.
  • Bustos M; Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France.
  • Torres-Ferreira J; Department of Translational Molecular Medicine, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, United States.
  • Henrique R; Cancer Biology and Epigenetics Group, Research Center (CI-IPOP)/P.CCC Porto Comprehensive Cancer Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Jeronimo C; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/P.CCC Porto Comprehensive Cancer Center, Porto, Portugal.
  • Lanfrancone L; Cancer Biology and Epigenetics Group, Research Center (CI-IPOP)/P.CCC Porto Comprehensive Cancer Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Delmas A; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/P.CCC Porto Comprehensive Cancer Center, Porto, Portugal.
  • Favre G; Department of Pathology and Molecular Immunology, Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
  • Daunay A; Cancer Biology and Epigenetics Group, Research Center (CI-IPOP)/P.CCC Porto Comprehensive Cancer Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Busato F; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/P.CCC Porto Comprehensive Cancer Center, Porto, Portugal.
  • Hoon DSB; Department of Pathology and Molecular Immunology, Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
  • Tost J; Department of Experimental Oncology, Instituto Europeo di Oncologia, Milan, Italy.
  • Etievant C; Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France.
  • Riond J; Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France.
  • Arimondo PB; Laboratory for Functional Genomics, Fondation Jean Dausset-CEPH, Paris, France.
Elife ; 112022 09 20.
Article in En | MEDLINE | ID: mdl-36125262
ABSTRACT
Aberrant DNA methylation is a well-known feature of tumours and has been associated with metastatic melanoma. However, since melanoma cells are highly heterogeneous, it has been challenging to use affected genes to predict tumour aggressiveness, metastatic evolution, and patients' outcomes. We hypothesized that common aggressive hypermethylation signatures should emerge early in tumorigenesis and should be shared in aggressive cells, independent of the physiological context under which this trait arises. We compared paired melanoma cell lines with the following properties (i) each pair comprises one aggressive counterpart and its parental cell line and (ii) the aggressive cell lines were each obtained from different host and their environment (human, rat, and mouse), though starting from the same parent cell line. Next, we developed a multi-step genomic pipeline that combines the DNA methylome profile with a chromosome cluster-oriented analysis. A total of 229 differentially hypermethylated genes was commonly found in the aggressive cell lines. Genome localization analysis revealed hypermethylation peaks and clusters, identifying eight hypermethylated gene promoters for validation in tissues from melanoma patients. Five Cytosine-phosphate-Guanine (CpGs) identified in primary melanoma tissues were transformed into a DNA methylation score that can predict survival (log-rank test, p=0.0008). This strategy is potentially universally applicable to other diseases involving DNA methylation alterations.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Elife Year: 2022 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Elife Year: 2022 Document type: Article Affiliation country: France